questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Tumeurs épithéliales épidermoïdes et glandulaires
Tumeurs kystiques, mucineuses et séreuses
Cystadénocarcinome
Cystadénocarcinome séreux
Cystadénocarcinome séreux : Questions médicales fréquentes
Diagnostic
5
Cystadénocarcinome séreux
Diagnostic médical
Imagerie médicale
Cystadénocarcinome séreux
Marqueurs tumoraux
Cystadénocarcinome séreux
Biopsie
Cystadénocarcinome séreux
Symptômes
Cystadénocarcinome séreux
Symptômes
5
Symptômes
Cystadénocarcinome séreux
Santé des femmes
Cystadénocarcinome séreux
Syndrome prémenstruel
Cystadénocarcinome séreux
Symptômes
Cystadénocarcinome séreux
Stadification
Cystadénocarcinome séreux
Prévention
5
Prévention
Cystadénocarcinome séreux
Antécédents familiaux
Cystadénocarcinome séreux
Mode de vie
Cystadénocarcinome séreux
Contraceptifs oraux
Cystadénocarcinome séreux
Suivi médical
Cystadénocarcinome séreux
Traitements
5
Chirurgie
Cystadénocarcinome séreux
Chirurgie
Cystadénocarcinome séreux
Chimiothérapie
Cystadénocarcinome séreux
Thérapies ciblées
Cystadénocarcinome séreux
Radiothérapie
Cystadénocarcinome séreux
Complications
5
Complications
Cystadénocarcinome séreux
Récidive
Cystadénocarcinome séreux
Effets secondaires
Cystadénocarcinome séreux
Chirurgie
Cystadénocarcinome séreux
Gestion des complications
Cystadénocarcinome séreux
Facteurs de risque
5
Facteurs de risque
Cystadénocarcinome séreux
Ménopause
Cystadénocarcinome séreux
Mutations BRCA
Cystadénocarcinome séreux
Tabagisme
Cystadénocarcinome séreux
Fertilité
Cystadénocarcinome séreux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cystadénocarcinome séreux : Questions médicales les plus fréquentes",
"headline": "Cystadénocarcinome séreux : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cystadénocarcinome séreux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-21",
"dateModified": "2026-07-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cystadénocarcinome séreux"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cystadénocarcinome",
"url": "https://questionsmedicales.fr/mesh/D003536",
"about": {
"@type": "MedicalCondition",
"name": "Cystadénocarcinome",
"code": {
"@type": "MedicalCode",
"code": "D003536",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.590.480"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cystadénocarcinome séreux",
"alternateName": "Cystadenocarcinoma, Serous",
"code": {
"@type": "MedicalCode",
"code": "D018284",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hui Liu",
"url": "https://questionsmedicales.fr/author/Hui%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Anesthesiology, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Ao Wang",
"url": "https://questionsmedicales.fr/author/Ao%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Gynecology and Obstetrics, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Yushan Ma",
"url": "https://questionsmedicales.fr/author/Yushan%20Ma",
"affiliation": {
"@type": "Organization",
"name": "Department of Anesthesiology, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Min Sun",
"url": "https://questionsmedicales.fr/author/Min%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, Tangdu Hospital, The Air Force Military Medical University, Xi'an, Shaanxi, China. sunmin_dr@163.com."
}
},
{
"@type": "Person",
"name": "Yu-Kun Li",
"url": "https://questionsmedicales.fr/author/Yu-Kun%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma.",
"datePublished": "2024-07-05",
"url": "https://questionsmedicales.fr/article/38970121",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13048-024-01464-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Primary Serous Cystadenocarcinoma of the Spleen.",
"datePublished": "2024-02-28",
"url": "https://questionsmedicales.fr/article/38558745",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.55165"
}
},
{
"@type": "ScholarlyArticle",
"name": "KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma.",
"datePublished": "2023-10-26",
"url": "https://questionsmedicales.fr/article/37916194",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/IJGM.S419235"
}
},
{
"@type": "ScholarlyArticle",
"name": "Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.",
"datePublished": "2023-10-11",
"url": "https://questionsmedicales.fr/article/37894756",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms242015077"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.",
"datePublished": "2023-09-03",
"url": "https://questionsmedicales.fr/article/37754507",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol30090592"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs épithéliales épidermoïdes et glandulaires",
"item": "https://questionsmedicales.fr/mesh/D009375"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs kystiques, mucineuses et séreuses",
"item": "https://questionsmedicales.fr/mesh/D018297"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cystadénocarcinome",
"item": "https://questionsmedicales.fr/mesh/D003536"
},
{
"@type": "ListItem",
"position": 7,
"name": "Cystadénocarcinome séreux",
"item": "https://questionsmedicales.fr/mesh/D018284"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cystadénocarcinome séreux - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cystadénocarcinome séreux",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cystadénocarcinome séreux",
"description": "Comment diagnostiquer un cystadénocarcinome séreux ?\nQuels examens sont nécessaires pour le diagnostic ?\nLe CA-125 est-il utile pour le diagnostic ?\nPeut-on diagnostiquer par biopsie ?\nQuels sont les signes d'alerte au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D018284#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cystadénocarcinome séreux",
"description": "Quels sont les symptômes courants ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nLes symptômes apparaissent-ils soudainement ?\nLes symptômes varient-ils selon le stade ?",
"url": "https://questionsmedicales.fr/mesh/D018284#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cystadénocarcinome séreux",
"description": "Peut-on prévenir le cystadénocarcinome séreux ?\nLes antécédents familiaux influencent-ils le risque ?\nLe mode de vie peut-il réduire le risque ?\nLes contraceptifs oraux ont-ils un effet préventif ?\nLe suivi médical est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D018284#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cystadénocarcinome séreux",
"description": "Quels traitements sont disponibles ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels médicaments sont utilisés en chimiothérapie ?\nY a-t-il des traitements ciblés ?\nQuel est le rôle de la radiothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D018284#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cystadénocarcinome séreux",
"description": "Quelles complications peuvent survenir ?\nLe cystadénocarcinome peut-il récidiver ?\nQuels sont les effets secondaires des traitements ?\nY a-t-il des risques liés à la chirurgie ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D018284#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cystadénocarcinome séreux",
"description": "Quels sont les principaux facteurs de risque ?\nLes femmes ménopausées sont-elles plus à risque ?\nLes mutations BRCA augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes antécédents de fertilité influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018284#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un cystadénocarcinome séreux ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'échographie, l'IRM et les marqueurs tumoraux comme le CA-125."
}
},
{
"@type": "Question",
"name": "Quels examens sont nécessaires pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les examens incluent l'échographie pelvienne et la tomodensitométrie (TDM)."
}
},
{
"@type": "Question",
"name": "Le CA-125 est-il utile pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le CA-125 est un marqueur tumoral souvent élevé dans les cystadénocarcinomes séreux."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être réalisée, mais le diagnostic est souvent confirmé par chirurgie."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'alerte au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des douleurs abdominales, des ballonnements et des changements urinaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs pelviennes, ballonnements, et troubles digestifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des irrégularités menstruelles et des douleurs pendant les rapports peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être similaires à ceux du syndrome prémenstruel ou d'autres tumeurs."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils soudainement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent apparaître progressivement, rendant le diagnostic précoce difficile."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le stade ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver avec l'avancement de la maladie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le cystadénocarcinome séreux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de cystadénocarcinome."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il réduire le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider à réduire le risque."
}
},
{
"@type": "Question",
"name": "Les contraceptifs oraux ont-ils un effet préventif ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que les contraceptifs oraux peuvent réduire le risque d'ovaires."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement d'éventuels problèmes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et parfois la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la chirurgie est souvent le traitement principal pour enlever la tumeur."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés en chimiothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme le carboplatine et le paclitaxel sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés peuvent être envisagés selon les caractéristiques tumorales."
}
},
{
"@type": "Question",
"name": "Quel est le rôle de la radiothérapie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie est rarement utilisée, mais peut être envisagée dans certains cas avancés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation de la maladie et des problèmes liés aux traitements."
}
},
{
"@type": "Question",
"name": "Le cystadénocarcinome peut-il récidiver ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque de récidive après traitement, nécessitant un suivi étroit."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue, et perte de cheveux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés à la chirurgie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques comme l'infection, les saignements et des complications anesthésiques existent."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et certaines mutations génétiques."
}
},
{
"@type": "Question",
"name": "Les femmes ménopausées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente après la ménopause en raison de changements hormonaux."
}
},
{
"@type": "Question",
"name": "Les mutations BRCA augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations BRCA1 et BRCA2 sont associées à un risque accru de cancers des ovaires."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que le tabagisme pourrait être un facteur de risque, mais les données sont variées."
}
},
{
"@type": "Question",
"name": "Les antécédents de fertilité influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de fertilité ou de traitements de fertilité peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 10/07/2026
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Anesthesiology, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Gynecology and Obstetrics, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Anesthesiology, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, Tangdu Hospital, The Air Force Military Medical University, Xi'an, Shaanxi, China. sunmin_dr@163.com.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. 765500072@qq.com.
Publications dans "Cystadénocarcinome séreux" :
2 publications dans cette catégorie
Affiliations :
Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. lihui_1973@126.com.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Surgery, Hull University Teaching Hospitals NHS Trust, Hull, GBR.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Pathology, Hull University Teaching Hospitals NHS Trust, Hull, GBR.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Surgery, Hull University Teaching Hospitals NHS Trust, Hull, GBR.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Surgery, Hull University Teaching Hospitals NHS Trust, Hull, GBR.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Department of Radiology, Baskent University School of Medicine, Dr. Turgut Noyan Medical and Research Center, Adana, Turkey.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Department of Radiology, Baskent University School of Medicine, Dr. Turgut Noyan Medical and Research Center, Adana, Turkey.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Department of General Surgery, Baskent University School of Medicine, Dr. Turgut Noyan Medical and Research Center, Adana, Turkey.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
Noncoding RNA and Drug Discovery Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, China.
Publications dans "Cystadénocarcinome séreux" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Publications dans "Cystadénocarcinome séreux" :
Ovarian serous cystadenocarcinoma, accounting for about 90% of ovarian cancers, is frequently diagnosed at advanced stages, leading to suboptimal treatment outcomes. Given the malignant nature of the ...
In this study, we analyzed the microbial contents of 453 ovarian serous cystadenocarcinoma and 68 adjacent non-cancerous samples. A univariate Cox regression model was used to identify microorganisms ...
Survival analysis revealed that patients in the low-risk group had a higher overall survival rate. A nomogram was constructed for easy visualization of the prognostic model. Analysis of immune cell in...
Our findings suggest that microbial profiles in ovarian serous cystadenocarcinoma may serve as viable clinical prognostic indicators. This study provides novel insights into the potential impact of in...
Tumours of the spleen are uncommon, and most are metastases from primaries in other organs. Primary splenic malignancies are subdivided into two main groups: lymphoid and non-lymphoid. Primary splenic...
Ovarian cancer (OV) is the highest prevalent gynecologic tumor with complicated pathogenesis; high-grade serous ovarian cystadenocarcinoma (HGSOC) is the most epidemiological and malignant subtype of ...
Bioinformatic analysis with various databases was conducted in this study. In details, KRT19 expression was assessed using databases including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expressio...
The expression of KRT19 was significantly upregulated in ovarian samples compared with normal controls. KRT19 expression was negatively associated with prognosis in OV, and further analysis revealed t...
This study demonstrated that KRT19 is a promising prognosis and diagnosis biomarker that determines cancer progression and is correlated with tumor immune cells infiltration in OV, suggesting being a ...
Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) ...
Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LG...
Low-density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is a member of the LDL receptor family and has often been discussed as a tumor suppressor gene, as its down-regulation is correlated w...
Due to the rarity of ovarian cancer diagnosed during pregnancy, the literature on the treatment of subtypes of epithelial ovarian cancer in pregnancy is sparse. The aim of our review was to analyze ca...
The PubMed and Scopus databases were searched for relevant articles published in English between January 2000 and December 2023. The references of all the relevant reviews found were also checked to a...
We found eleven cases with relevant details of high-grade serous ovarian cancer diagnosed in pregnancy. Despite the small number of cases we found, our study demonstrated the importance of an accurate...
There have not been long-term follow-ups of patients' oncologic and obstetric outcomes. As patients should be comprehensively informed, more detailed case reports or series with longer follow-up perio...
Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects ...
Serous ovarian carcinoma (SOC) is a biologically heterogeneous with different genomic and molecular profiles, beside clinical response to the chemotherapy with subsequent in obstacles in starting unif...
In this study, the immunoexpression of Nanog, ZEB1, and EpCAM was studied in 60 cases of SOC. Overall survival (OS), disease-free survival (DFS) data and response to chemotherapy were analyzed....
NANOG was immunostained in 65% of the cases with a significant association with tumor grade, lymph node metastasis, and FIGO stage (p < 0.001 for each). ZEB1 showed moderate- high expression in 58.3% ...
Up-regulation of Nanog and ZEB-1 and EpCAM perhaps promote an aggressive SOC with a high risk of relapse and unfavorable response to standard chemotherapy regimen....
High-grade serous ovarian cancer (HGSOC) is an aggressive disease known to develop resistance to chemotherapy. We investigated the prognostic significance of tumor cell states and potential mechanisms...